Incretin mimetics have demonstrated safety and efficacy in advanced kidney disease, however multiple studies have shown that use of GLP1-RA have shown improvements in glycemic control, body weight reductions, improved beta cell function, and decreased incidence hypoglycemia as compared to DPP4i in a general diabetes population 26,27,28,29,30,31 , effects which might explain the reduction of acute healthcare utilization observed in this study of patients with CKD treated with GLP1-RA as compared to DPP4i
But it also means the dosing protocol carries more complexity than a single-agonist compound like semaglutide or even the dual-agonist tirzepatide
Plus, if you're pushing through intense workouts or making major lifestyle changes, your body may simply be overstimulated
Studies have examined the relationship between NNMT inhibition and cellular NAD+ levels, which are critical for numerous enzymatic reactions including those involving sirtuins and PARPs
It is expected to be commercially available in pharmacies in the second quarter of 2026